Bukwang Pharm. announced that first dosing of the pharmacokinetic clinical trial of JM-010 was carried out on 26th of July. JM-010 is a new drug candidate to treat levodopa-induced dyskinesia (LID; movement disorder caused by levodopa treatment in Parkinson’s disease patients) developed by Contera Pharma, a CNS-specialized bio-venture and Bukwang’s subsidiary.
Bukwang’s representative said, “Levodopa-induced dyskinesia occurs inevitably in 60~70% of Parkinson’s disease patients who receive long-term levodopa treatment, which is a gold standard for treatment of Parkinson’s disease. The Proof-of-Concept phase 2a clinical trial of JM-010, a proposed treatment for this movement disorder, was already completed in South Africa. The current pharmacokinetic study is ongoing in Germany following IND approval in Europe. We are aiming to finish the study until the end of this year and initiate phase 2b clinical trial in the first half of 2017.”
Bukwang has recently been strengthening its R&D efforts in developing innovative new drugs in various therapeutic areas including diabetes, cancer and CNS disorders.
“Bukwang plans to focus its resources on finding growth opportunities by entering the overseas market through new drug development, rather than relying on the domestic market,” Bukwang’s representative added.